News Article

MicroIslet Announces Voluntary Reorganization Filing
Date: Nov 10, 2008
Source: GlobeNewswire ( click here to go to the source)

Featured firm in this article: MicroIslet Inc of San Diego, CA

MicroIslet Inc. (OTCBB:MIIS) (, a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, today announced that it filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code. The company plans to continue operating the business without interruption as management focuses on developing and executing on a corporate restructuring plan.

"During the past 16 months we believe we have made substantial progress toward the goal of getting the Company's lead product, MicroIslet-P(tm), ready for human clinical trials," said Michael J. Andrews, chief executive officer of MicroIslet. "Unfortunately, during that period of time capital markets have not responded to these advances, and we have not been able to secure significant funding as a public company. Our objective now is to simplify our capital structure in order to attract debtor-in-possession financing. These actions are designed to enable us to complete and file the MicroIslet-P(tm) Investigational New Drug application (IND) with the FDA, and to emerge from the bankruptcy proceedings as a private company."

MicroIslet has also filed a series of motions with the Bankruptcy Court to assure the continuity and stability of the business, including the payment of wages, and payments to certain critical vendors. MicroIslet expects operations to continue as usual throughout the process.

About MicroIslet

MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of cell therapy for patients with insulin-dependent diabetes. MicroIslet has licensed several technologies from Duke University for isolation, culturing, storage, and microencapsulation of insulin-producing islet cells from porcine sources. The Company believes that these technologies, and other proprietary methods developed in-house, are significant advances in the field of cellular therapeutics. MicroIslet is planning human clinical trials in the U.S., and exploring possible trials abroad. MicroIslet's ultimate goal is to offer cell transplantation therapies for diabetic patients worldwide.

The Company's lead product, MicroIslet-P(tm), consists of microencapsulated porcine islets for implantation into the abdominal cavity using a minimally invasive procedure. Microencapsulation involves surrounding islet cells with formulations of a highly biocompatible, ultra-pure biopolymer, called alginate, or other similar biocompatible polymers. The alginate coating allows insulin, glucose, oxygen and other nutrients to diffuse freely, while blocking antibodies and reducing the patient's immune response to the implanted islet cells. It is hoped that MicroIslet-P(tm) will provide physiologic and self-regulating blood glucose control, thus reducing the need for insulin injections or infusions and constant blood glucose monitoring. The long term complications associated with type 1 diabetes, such as peripheral neuropathies, heart and kidney disease, and skin disorders, may be mitigated by the tighter blood glucose control that would result from such a product. Additional information about MicroIslet can be found at
- See more at: